Reluctancy Waltz

Tracing a neat straight line, adept and sure, The falcon heeds the calling falconer; Things hang together, and the center holds; Mere symmetry is ordering the world, The sea-bright tide is loosed, and everywhere The ceremony of innocence proceeds; The best have strong convictions, while the worst Are full of resignation and are sad.

First: THIS RECALL IS NOT STATE SPECIFIC. IT IS NATIONWIDE.

here are the specific products and dates:

FDA page on this:

A habitable, equal and prosperous 21st century is materially possible. The carbon budget allows it and history offers precedents at comparable scales: universal suffrage, the universalisation of healthcare and education, the halving of working hours and the sharp compression of inequality over the 20th century. Technical impossibility is not what is standing in the way, but rather the absence of a shared vision of social progress, at once concrete and radical. What it will take instead is political choice, and the hard work of coalition-building behind it.

—

Ground News - Somali Referee Denied US Entry Before World Cup

He carries a DIPLOMATIC PASSPORT.

Fuck Trump. Fuck ICE. Fuck everything about this. 

A topic that would come up, not exactly often, but regularly enough to be noticeable, was "who is it we should be restricting from voting?" Popular responses included: dual citizens; citizens who live abroad; citizens who were born to immigrant parents; citizens who didn't pay income taxes; citizens who hadn't served in the military; Muslims; and, of course, women.

Two little things that made this even more interesting. One, it was never the actual bloggers who prompted it. I never saw a post titled "How To Improve Our Electorate By Restricting Voting." It always arose spontaneously in the comments section. Two, I never saw anybody push back. Not once did a commenter say "guys, is it really okay to stop people from voting because we don't agree with their politics?" It was always completely explicit: we have to do this because those demographics vote Democrat.

Which says so much about how utterly mainstream and widely accepted this position is in red states.

So. This is a bit about Good Omens, but actually about a lot of queer stories with cynical or outright unhappy endings.

I think people like NG(fuck him sideways with a stick) see happy endings as overdone, cliche, old fashioned, predictable. If you want to be subversive, edgy and cool, you need to have a tragic ending, or an ambivalent one, or a cynical one.

But the thing is, if you're writing a queer story, you're writing for an audience that rarely gets a happy ending. The queers rarely get to live happily ever after in a joyful world. That's why we so deeply appreciate stories that celebrate queer joy. Because it's so rare.

So these (mostly) heterosexual (mostly) men write queer stories for queer audiences and don't realise that for us, we expect the tragedy, the ambivalence, the cynicism. For us, if you want to be subversive, write that happy ending, that hopeful ending, that affirmative ending. We won't expect it. I promise. You can be an edgelord by subverting the queers have to suffer trope. We will all be impressed by your audacity. I promise.

"For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.

That routine just changed.

On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.

This is not a minor update to an existing drug.

It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.

Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.

That means reducing from 365 injections a year down to just 52.

For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.

It represents relief.

How the Drug Actually Works

Understanding why this injection lasts a full week requires a quick look inside the body.

Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.

Awiqli works differently.

Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.

This attachment creates a slow-release reservoir.

Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...

The FDA reviewed and ultimately declined to approve it for people with type 1 diabetes, citing concerns about a modestly increased risk of hypoglycemia in that population specifically.

Some regulatory agencies in other countries, including the European Union, Canada, Australia, and Japan, have approved Awiqli for both type 1 and type 2 diabetes, but for now the U.S. approval is limited to type 2...

What Comes Next

Awiqli is not standing alone in this space for long.

Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.

If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.

The broader direction of travel in diabetes care is unmistakable.

Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...

A Small Shot With Large Implications

It is easy to look at a once-weekly injection and see only a scheduling change.

But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.

Diabetes management has always asked a lot of people.

It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.

Anything that reduces that load, without reducing the quality of care, is worth taking seriously.

For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.

That is the real significance of what the FDA approved on March 26, 2026.

Not just a new drug.

A new way of keeping people healthy, one week at a time."